Skip to main content

Astria Therapeutics, Inc.

ATXSDelisted Jan 23, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001454789

Astria Therapeutics, Inc. was delisted on Jan 23, 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.2M in total; Soros Fund Management was the only superinvestor holding it.

Q2 2025 vs. Q1 2025

How the institutions holding Astria Therapeutics, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of ATXS: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders116106−10
Shares58.3M57.6M−768.6K (−1.3%)
Value$311.4M$309.9M−$1.55M (−0.5%)

New holders (14)

Institutions that held Astria Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to ATXS in Q2 2025
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.762,756$4.09M0.01%
Affinity Asset Advisors, LLC300,000$1.61M0.24%
Panagora Asset Management Inc98,458$527.7K0.00%
Cantor Fitzgerald, L. P.54,635$292.8K0.01%
XTX Topco Ltd36,249$194.3K0.01%
EntryPoint Capital, LLC33,375$178.9K0.09%
Bailard, Inc.26,500$142.0K0.00%
HRT Financial LP22,366$119.0K0.00%
Squarepoint Ops LLC19,862$106.5K0.00%
Susquehanna Portfolio Strategies, LLC17,900$95.9K0.00%
1620 Investment Advisors, Inc.2,000$10.7K0.01%
Versant Capital Management, Inc298$1.60K0.00%
The PNC Financial Services Group, Inc.145$7770.00%
Parkside Financial Bank & Trust90$4830.00%

Sold out (24)

Institutions that held Astria Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.